Abstract: The present teaching provide indazole compounds represented by Structural Formulae (I) or (I?) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

Abstract: The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.

Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.

Abstract: The present invention discloses a method for securing information flow in an information system. The method comprises intercepting access requests to information in the information system by all applications running in the information system, intuitively assigning labels to all the information and the applications depending on the application requirements, combining the application making the access request and the information for which the access request is made with their respective labels, checking allowance of the access request based on comparison of the label corresponding to the application making the access request and the label corresponding to the information for which the access request is made and accordingly providing access of the information to the application on detection of allowable access request else denying the access request.

Abstract: Systems and methods are disclosed for improving Physical Downlink Control Channel (PDCCH) allocation for improved downlink scheduling. In some embodiments, a method of operation of a network node in a cellular communications network comprises transmitting a downlink assignment to a wireless device, the downlink assignment comprising an indication of whether the downlink assignment applies to a single Transmit Time Interval (TTI) or multiple consecutive TTIs, and transmitting a downlink data transmission to the wireless device during a single TTI or multiple downlink data transmissions to the wireless device during multiple consecutive TTIs according to the downlink assignment. In this manner, the network node does not need to transmit, and the wireless device does not need to receive/decode, a separate downlink assignment in each TTI. This may be beneficial to, e.g., mitigate PDCCH congestion.

Abstract: The present invention discloses a method for securing information flow in an information system. The method comprises intercepting access requests to information in the information system by all applications running in the information system, intuitively assigning labels to all the information and the applications depending on the application requirements, combining the application making the access request and the information for which the access request is made with their respective labels, checking allowance of the access request based on comparison of the label corresponding to the application making the access request and the label corresponding to the information for which the access request is made and accordingly providing access of the information to the application on detection of allowable access request else denying the access request.

Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.

Abstract: The present invention provides a method for screening compounds for their ability to inhibit autophosphorylation of Janus kinase 3 in the absence of any additional substrate. The present invention also provides a method for screening compounds that bind to Janus kinase 3 domains other than the kinase domain, to identify synthetic or natural compounds including biomolecules, that modulate Janus kinase 3 activity. This invention also describes a multi-component screening kit composed of purified recombinant Janus kinase 3 proteins and recombinant phosphorylated Janus kinase 3 fusion proteins including, one or more phosphorylated or non-phosphorylated domain-deleted Janus kinase 3 fusion proteins.

Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: Systems and methods are disclosed herein that relate to automated measurement and analysis of end-to-end performance of Voice over Long Term Evolution (VoLTE) service and, in some embodiments, automated network optimization for VoLTE service performance improvement. In some embodiments, a method of operation of a network node to perform automated end-to-end analysis of VoLTE sessions is provided. In some embodiments, the method of operation of the network node comprises correlating control and data plane messages across a nodes and interfaces in a VoLTE network to thereby provide data representative of end-to-end message flows for a plurality of VoLTE sessions. The method of operation further comprises configuring one or more nodes in the VoLTE network based on the data representative of the end-to-end message flows for the plurality of VoLTE sessions. In this manner, automated network optimization for VoLTE service performance improvement can be provided.

Abstract: A fleet manager within a cloud computing system utilizes a registration framework with one or more cloud infrastructure managers having corresponding infrastructure data plane nodes, which may be in use by different tenants. Instead of having the infrastructure managers communicate directly with its corresponding infrastructure data plane nodes via a management network or domain, the fleet manager communicates with infrastructure managers and relay commands, instructions, and other payloads to the infrastructure data plane nodes using a virtual machine (VM) communication backchannel.

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract: A system and method to sustain an on-going voice call or other service during a handover, HO, by preventing the handover to a target cell that fails to admit all the mandatory Radio Access Bearers, RABs, as part of supporting one or more Quality of Service Class Identifiers, QCIs, associated with the ongoing service. When the source evolved Node B, eNB, prevents the HO to the best target cell, it may attempt the HO to the next best target cell. If the next best cell fails to admit all the mandatory RABs and if there are no other intra-LTE or inter-LTE cells available for HO, the source eNB may perform an inter-Radio Access Technology, RAT, HO using the Single Radio Voice Call Continuity, SRVCC, procedure. By preventing “partial” handovers, the retainability of an ongoing service is significantly improved. The target cells causing failure of particular RABs can be tracked using new counters.

Abstract: Janus Kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of Jak3 was associated with human hematologic and epithelial malignancies. Inhibitors of Jak3 have shown utility in many different disease such as autoimmune disorders, allograft rejection during transplantation, acute lymphoblastic leukemia, Type 1 diabetes, rheumatoid arthritis and allergy and asthma. Since these inhibitors make their way into clinical trials with profound effects, it is essential to develop a sensitive, precise, and rugged screening tool to screen synthetic compounds or other biomolecules that has the potential to modulate Jak3 functions and hence treat a wide variety of diseases. Present invention relates to novel high throughput system for finding previously unknown Jak3 interacting compounds, human biomolecule (e.g. proteins or others), and those compounds that can inhibit Jak3 activations.

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: Emulating a NIC for packet transmission on hardware RSS unaware NICs in a multi-core system enables each of a plurality of slave packet engines to emulate a NIC for packet transmissions locally even though the actual NIC transmissions from the queue are handled by a master packet engine only. Each slave packet engine treats a local software-implemented transmission queue as a device queue and uses the local queue to keep track of status of data from the packet engine in the device output queue, handled by the master packet engine on behalf of the slave packet engines. As the master packet engine transmits the data from the queue and the status of the queue changes, the master packet engine and the slave packet engines may use pointers to keep track of which data packets are transmitted, which data packets are drained and which data packets are still in the queue.

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.